UK Funding for Sanfilippo Disease
Analysis based on 8 articles · First reported Mar 23, 2026 · Last updated Mar 23, 2026
The potential for new treatments for rare genetic disorders like Sanfilippo disease could significantly impact the biotechnology and pharmaceutical industries, driving investment in gene therapy research. Government funding for clinical trials, particularly from the United Kingdom, would accelerate the development and accessibility of these treatments, potentially creating new market opportunities.
The parents of two-year-old Leni Forrester are in a desperate race against time to secure treatment for their daughter, who has been diagnosed with Sanfilippo disease, a rare genetic neurodegenerative disorder often referred to as childhood dementia. This condition causes progressive damage to the brain due to an enzyme deficiency, leading to a loss of physical and cognitive abilities. Currently, there is no cure or approved treatment in the United Kingdom. A clinical trial for a new treatment is expected to begin in the United States later this year. Leni's parents are appealing to the United Kingdom government to fund research into this trial, hoping to include British children. Professor Brian Bigger from the University of Edinburgh has pioneered a gene therapy approach for Sanfilippo disease, but substantial funding is required to initiate clinical trials. The United Kingdom — Department of Health and Social Care has acknowledged the situation and stated its commitment to improving diagnosis and access to treatment for rare diseases.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard